Weight and glycaemic control in type 2 diabetes: What is the outcome of insulin initiation?

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 823-831

  Watson, L ^a   Wilson, B P ^b   Alsop, J ^c   Kumar, S ^d  

^a EPIPharmaCo Ltd   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c Numerus Statistics Ltd   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Glycaemic control; Insulin; Obesity; Type 2 diabetes

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN;

EID: 79960769095     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01413.x     Document Type: Article

References (25)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
2. NICE. NICE clinical guideline 87 (Clinical Update of NICE clinical guideline 66). London: NICE, 2009; Report No.: CG87.
3. The task force on Diabetes and Cardio-Vascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Guideline on diabetes, pre-diabetes and cardio-vascular disease: full text. ESD, EASD, 2007.
4. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Glycemic management. Endocr Pract 2007; 13(Suppl. 1): 16-34.
5. Valensi P, Benroubi M, Borzi V et al. The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Prac 2008; 62: 1809-1819.
6. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008; 10(Suppl. 1): 8-15.
7. Freemantle N, Holmes J, Hockey A, Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Prac 2008; 62: 1391-1396.
8. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2009; 12: 62-66.
9. McGarry JD. The Banting Lecture: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
10. Rathmann W, Strassburger K, Kostev K, Schroder-Bernhard D, Giani G, Happich M. Longitudinal change in HBA1c in patients with type 2 diabetes: comparison of short-acting biphasic and basal insulin. Exp Clin Endocrinol Diabetes 2009; 117: 230-233.
11. Russell-Jones D, Khan R. Insulin associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2009; 9: 799-812.
12. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007; 29: 1236-1253.
13. Jacobs ML, Elte JW, van Ouwerkerk BM et al. Effect of BMI, insulin dose, and number of injections on glycaemic control in insulin-using diabetic patients. Studygroup Diabetes Rijnmond (SDR). Neth J Med 1997; 50: 153-159.
14. Graber AL, Shintani AK, Wolff K, Brown A, Elasy TA. Glycemic relapse in type 2 diabetes. Endocr Pract 2009; 12: 145-151.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
16. Biesenbach G, Rami A, Alsaraji N. Weight gain and insulin requirement in T2DM patients during the first year after initiating insulin therapy dependent on baseline BMI. Diabetes Obes Metab 2006; 8: 669-673.
17. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-768.
18. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2009; 32(Suppl 1): S13-61.
19. Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J Clin Prac 2008; 62: 1647-1653.
20. Chambers JC, Shinichi E, Bassett P et al. C-reactive protein, insulin resistance, central obesity and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-150.
21. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilisation. JAMA 1997; 278: 1663-1669.
22. Hirsh IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
23. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJ Med 2009; 93: 369-374.
24. Aas AM, Ohrvik J, Malmberg K, Rydén L, Birkeland KI, DIGAMI 2 Investigators. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes Obes Metab 2009; 11: 323-329.
25. Aucott L, Poobalan A, Smith WC et al. Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes-a systematic review. Diabetes Obes Metab 2004; 6: 85-94.